论文部分内容阅读
Boot 公司的充血性心衰药氟司喹南(flosequinan,商品名 Manplax)已被美国批准。该产品将于1993年3月上市,并和 Parke Davis 联合组成了总数达700多人的销售队伍来共同开拓市场。在美国的适应症是治疗充血性心衰病
Boot’s congestive heart failure drug flosequinan (flosequinan, trade name Manplax) has been the United States approved. The product will be marketed in March 1993 and, together with Parke Davis, formed a combined sales force of more than 700 to jointly develop the market. Indications in the United States is the treatment of congestive heart failure